TY - JOUR
T1 - Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling
AU - Wykoff, Charles C.
AU - Pugh, Christopher W.
AU - Maxwell, Patrick H.
AU - Harris, Adrian L.
AU - Ratcliffe, Peter J.
N1 - Funding Information:
This work was supported by the Wellcome Trust, the Medical Research Council, and the Imperial Cancer Research Fund.
PY - 2000/12/14
Y1 - 2000/12/14
N2 - The von Hippel-Lindau tumour suppressor gene (VHL) targets hypoxia inducible factor (HIF)-α subunits for ubiquitin dependent proteolysis. To better understand the role of this and other putative pathways of gene regulation in VHL function we subjected mRNA from VHL defective renal carcinoma cells and transfectants re-expressing a wild type VHL allele to differential expression profiling, and analysed VHL target genes for oxygen regulated expression. Among a group of newly identified VHL target genes the majority but not all were regulated by oxygen, indicating that whilst dysregulation of the HIF system makes a dominant contribution to alterations in transcription, VHL has other influences on patterns of gene expression. Genes newly defined as targets of the VHL/hypoxia pathway (conditionally downregulated by VHL in normoxic cells) include aminopeptidase A, collagen type V, alpha 1, cyclin G2, DEC1/Stra13, endothelin 1, low density lipoprotein receptor-related protein 1, MIC2/CD99, and transglutaminase 2. These genes have a variety of functions relevant to tumour biology. However, not all are connected with the promotion of tumour growth, some being pro-apoptotic or growth inhibitory. We postulate that co-ordinate regulation as part of the HIF pathway may explain this paradox, and that evolution of anti-apoptotic pathways may be required for tumour growth under VHL-dysregulation. Our results indicate that it will be necessary to consider the effects of abnormal activity in integral regulatory pathways, as well as the effects of individual genes to understand the role of abnormal patterns of gene expression in cancer.
AB - The von Hippel-Lindau tumour suppressor gene (VHL) targets hypoxia inducible factor (HIF)-α subunits for ubiquitin dependent proteolysis. To better understand the role of this and other putative pathways of gene regulation in VHL function we subjected mRNA from VHL defective renal carcinoma cells and transfectants re-expressing a wild type VHL allele to differential expression profiling, and analysed VHL target genes for oxygen regulated expression. Among a group of newly identified VHL target genes the majority but not all were regulated by oxygen, indicating that whilst dysregulation of the HIF system makes a dominant contribution to alterations in transcription, VHL has other influences on patterns of gene expression. Genes newly defined as targets of the VHL/hypoxia pathway (conditionally downregulated by VHL in normoxic cells) include aminopeptidase A, collagen type V, alpha 1, cyclin G2, DEC1/Stra13, endothelin 1, low density lipoprotein receptor-related protein 1, MIC2/CD99, and transglutaminase 2. These genes have a variety of functions relevant to tumour biology. However, not all are connected with the promotion of tumour growth, some being pro-apoptotic or growth inhibitory. We postulate that co-ordinate regulation as part of the HIF pathway may explain this paradox, and that evolution of anti-apoptotic pathways may be required for tumour growth under VHL-dysregulation. Our results indicate that it will be necessary to consider the effects of abnormal activity in integral regulatory pathways, as well as the effects of individual genes to understand the role of abnormal patterns of gene expression in cancer.
KW - HIF-1α
KW - Hypoxia
KW - VHL
UR - http://www.scopus.com/inward/record.url?scp=0034649507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034649507&partnerID=8YFLogxK
U2 - 10.1038/sj.onc.1204012
DO - 10.1038/sj.onc.1204012
M3 - Article
C2 - 11175344
AN - SCOPUS:0034649507
SN - 0950-9232
VL - 19
SP - 6297
EP - 6305
JO - Oncogene
JF - Oncogene
IS - 54
ER -